Antiplatelet therapy in percutaneous coronary intervention: is variability of response clinically relevant? | Heart

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BCS

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Article Text

Education in Heart

Interventional cardiology

Antiplatelet therapy in percutaneous coronary intervention: is variability of response clinically relevant?

https://doi.org/10.1136/hrt.2010.206508

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

Competing interests In compliance with EBAC/EACCME guidelines, all authors participating in Education in Heart have disclosed potential conflicts of interest that might cause a bias in the article. Nick Curzen has received unrestricted research funding from Haemonetics, Medtronic, Boston Scientific and Pfizer. He has also received speaker fees/consultancy from Boston Scientific, Abbott, Medtronic, AstraZeneca, Lilly and Cordis.
Provenance and peer review Commissioned; internally peer reviewed.

Read the full text or download the PDF: